Month: October 2015

October 2, 2015
First longer-acting FVIII moves a step closer

28 September 2015 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorisation of Elocta. Once approved, Elocta will likely be the first prolonged half-life treatment option available for people with haemophilia A in the UK and Ireland. Elocta is a recombinant factor VIII Fc fusion …

Read article